For journalists, writers, broadcasters, commentators or researchers looking for comment relating to ICON or the broader CRO industry.
Innovative clinical trial designs that take advantage of our in depth statistical expertise.
Fast delivery of high quality and meaningful data means that you can make well informed decisions earlier in the trial. This also ensures patient protection and reliable trial results.
Endpoint Adjudication can help to lower the risk of variation in important clinical trial outcome events for submission to regulatory agencies.
Timely and accurate Investigator payments are critical for keeping sites motivated and driving site performance in a study.
Scaling Up CAR-T Therapies Requires Overcoming Manufacturing, Regulatory and Distribution Challenges.
Patient centric strategies to focus more on patient needs and increase efficiencies.
Biostatistics: Using Restricted Mean Survival Time (RMST) in Oncology Trials to Improve Outcomes.
Biomarker-based methods and how they can be leveraged to add value to oncology trials.
ICON has been immersed in the development of both passive and active immunotherapy approaches, allowing sponsors to overcome challenges in Immuno-Oncology.
the discovery of novel biomarkers has made MMMultiple Myeloma diagnosis and monitoring much easier and more efficient.
The evolution of adoptive cellular transfer (ACT) for the treatment of lymphoma, leukaemia and myeloma patients has grown exponentially.
Although Asia Pacific (APAC) is sometimes referred to as a homogenous unit, it is a heterogeneous region, with divergent countries, languages, populations and cultures.